Cannabis
HHC got its own drug code, and the reasoning matters more than the listing
On 4 May 2026 the DEA gave hexahydrocannabinol its own listing and drug code in Schedule I (Docket DEA-1632, effective the same day). HHC was already a Schedule I controlled substance as a tetrahydrocannabinol, so its status did not change. What the rule sets out plainly is why: a THC made by chemical conversion is synthetic, even when the input is hemp.
The rule is administrative. The DEA states that hexahydrocannabinol has been controlled in Schedule I as a tetrahydrocannabinol, that all regulations and criminal sanctions applicable to Schedule I substances have been and remain applicable to it, and that this action does not affect its continuing status in any way. It establishes a separate specific listing and assigns a drug code. The action followed a United Nations decision placing HHC in Schedule II of the 1971 Convention.
The part that reaches operators is the discussion of the hemp definition. The Agriculture Improvement Act of 2018 removed "tetrahydrocannabinols in hemp" from control and defined hemp as the plant and its derivatives, extracts, cannabinoids, isomers, acids and salts with a delta-9-THC concentration of not more than 0.3 percent on a dry weight basis (7 U.S.C. 1639o(1)).
The DEA reads that exclusion narrowly, and says so: only tetrahydrocannabinols in or derived from the cannabis plant, not synthetic tetrahydrocannabinols, are excluded from control. It goes further — tetrahydrocannabinols produced through chemical conversion are considered synthetically produced for purposes of the Controlled Substances Act "even when hemp derived", and do not qualify as tetrahydrocannabinols in hemp.
That sentence is the one a hemp-derived product business should read closely, because a great deal of the category is made by converting CBD. Whether a particular product is within the hemp exclusion turns on how the cannabinoid in it was actually produced, which is a question about the manufacturing process and the documentation behind it.
What changed
Hexahydrocannabinol now has its own specific listing and DEA drug code in Schedule I.
What did not change
Its legal status. The DEA states expressly that HHC was already controlled in Schedule I as a tetrahydrocannabinol and that this action does not affect that in any way.
Who this reaches
Anyone manufacturing, distributing or selling hemp-derived cannabinoid products, particularly where a cannabinoid is produced by chemical conversion rather than extracted from the plant. The listing took effect on 4 May 2026, but the reasoning applies to the whole category and not only to HHC.
Common questions
Was HHC legal before this rule?
The DEA position is that it was not. The rule states that hexahydrocannabinol, by meeting the definition of tetrahydrocannabinols and being synthetically produced, has been controlled in Schedule I, and that the regulations and criminal sanctions applicable to Schedule I substances have been and remain applicable to it. The rule assigns a drug code rather than changing status.
Does the 2018 Farm Bill protect a hemp-derived cannabinoid?
Only where it is in or derived from the cannabis plant and within the 0.3 percent delta-9-THC limit. The DEA states in this rule that tetrahydrocannabinols produced through chemical conversion are synthetically produced for CSA purposes even when hemp derived, and do not qualify as tetrahydrocannabinols in hemp.
What does this mean for a hemp beverage line?
It makes the manufacturing route a legal question and not only a supply question. Whether the cannabinoid was extracted or converted, what the supplier documentation shows, and what the certificate of analysis actually establishes are the things a regulator would look at. State law adds a further layer and is separate from this.
Does this reach your business?
Every matter turns on its facts. Mr. Sheehan reviews each inquiry himself.